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ABSTRACT 
 Objective:  Group metrics are described to quantify blood glucose (BG) variability of hospitalized 
patients.     
 Methods:  The “multiplicative surrogate standard deviation” (MSSD) is the reverse-transformed 
group mean of the standard deviations (SD) of the logarithmically-transformed blood glucose (BG) data 
set of each patient.  The “geometric group mean” (GGM)  is the reverse-transformed group mean of the 
means of the logarithmically-transformed BG data set of each patient.    Before reverse-transformation 
is performed, the mean of means and mean of SD’s each has its own SD, which becomes a multiplicative 
standard deviation (MSD) after reverse-transformation.  Statistical predictions and comparisons of 
parametric or nonparametric tests remain valid after reverse-transformation.  A subset of a previously-
published BG data set of 20 critically ill patients from the first 72 hr of treatment under the SPRINT 
protocol was transformed logarithmically.  After rank-ordering according to the mean of the SD of the 
logarithmically-transformed BG data of each patient, the cohort was divided into 2 equal groups, those 
having lower or higher variability.    
 Results:  For the entire cohort, the GGM was 106 mg/dL (÷/× 1.07),  and MSSD was 1.24 ( ÷/×  
1.07).   For the subgroups having lower and higher variability respectively, the GGM in mg/dL did not 
differ,  104( ÷/× 1.07)  vs.  109 ( ÷/× 1.07), but the MSSD differed, 1.17 ( ÷/× 1.03) vs. 1.31 (÷/× 1.05), p = 
0.00004.   
 Conclusion:  By using the MSSD with its MSD, groups can be characterized and compared 
according to glycemic variability of individual patient members.   
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INTRODUCTION 
Observational data suggest that across a wide variety of settings and medical conditions, and perhaps 
independently of overall glycemia or hypoglycemia, the outcomes of hospitalized patients may be 
associated with glycemic variability.  Our understanding of the impact of glycemic variability has been 
hampered in some studies by failure to apply variability metrics separately to the blood glucose (BG) 
distribution of each patient prior to analysis of group characteristics.  Observational studies examining 
central tendency and dispersion of BG of each patient have been hampered by timing of blood glucose 
tests at sporadic intervals.  Additionally, we lack methodologies for controlling variability, by which a 
randomized controlled trial might be attempted.   In this paper we address an additional barrier, the lack 
of consensus on an appropriate metric for glycemic variability for hospitalized patients, by proposing use 
of a group metric that permit quantitative description and group comparisons of glycemic variability 
experienced by individual group members. 
 To study the impact of variability upon patient outcomes, it is important to recognize and 
quantitate patient level glycemic variability of individuals and subgroups.  In a number of studies, the 
standard deviation (SD) of the BG of the individual patient has been shown to correlate with hospital 
outcomes 1-6.   A major time-dependent change of overall glycemia could alter the dispersion of BG in 
relation to the overall mean BG on the time interval during which the sampling occurred, increasing the 
SD without necessarily signifying  a pattern of recurring large oscillations 7.  It is acknowledged that 
infrequent sampling results in missing of peaks and nadirs of BG.  However, if the moving average of BG 
is relatively stable, and if timing of sampling is consistent, then SD may mirror the relative amplitude of 
typical glycemic excursions among patients within a group.   Therefore, many authors consider the SD to 
be a variability metric.  Despite its record of performance as a predictor of outcomes, nevertheless the 
SD is misapplied when used for data sets that are not normally distributed.  Population and individual 
patient BG distribution data typically are positively skewed 8-10, such that use of SD for untransformed 
data is not appropriate for description of dispersion or for utilization of parametric statistical tests that 
assume a normal distribution of data.  Studies reporting SD can yield results that could predict among 
patients in the lowest BG range that some BG values would be less than zero 2.   
 BG data often are capable of being normalized by logarithmic transformation 9-11.  If original data 
generally has a distribution that is close to log-normal, then the purpose of the logarithmic transform is 
to gain the advantages of representing the same data points as members of a normal distribution.  The 
BG distribution characteristically seen has a positive skew (a long tail to the right), and with mean 
greater than median.  One advantage of performing logarithmic transformation is to put the data into a 
symmetrical form in which the mean approximates the median, and the calculated SD creates specific 
expectations under an empirical rule, predicting the percentages of measurements falling symmetrically 
within 1 or 2 SD of the mean.  Group metrics can be performed on the logarithmically transformed data.   
If the transformation creates a normally distributed data set, then, assuming other conditions are met 
(such as independence of observations), between-group analyses using parametric tests are potentially 
valid.   Reverse transformation serves the purpose of returning  values that are in units of measure 
familiar to the reader, on the same scale as the original data.  A standard deviation which is added or 
subtracted in “log space” to give interval bounds becomes a multiplicative SD after reverse 
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transformation.   Interval bounds are given as a mean ( ± SD) in “log space” or, after reverse 
transformation, in more familiar units the interval bounds are given as mean ( ÷ / x multiplicative SD).   
 The purpose of this report is to describe a process for computing a specific descriptive group 
metric for glycemic variability experienced by individual patients, which we will call a “multiplicative 
surrogate SD”   of the blood glucose or MSSD.   Use of such a metric has been suggested previously 6.  
Here we wish to describe its multiplicative characteristics and the details of its application when used 
together with an artificial geometric mean, which would represent values characteristic of a group 
member of a cohort (an artificial patient).  Since we believe the need for descriptive nomenclature has 
been a barrier to development of appropriate metrics, we suggest the names “geometrical group mean” 
(GGM) and “multiplicative surrogate standard deviation” (MSSD) to succinctly denote the metrics 
described below (Figure 1). 
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METHODS 
Description of method 
The purpose is to describe a variability metric representing dispersion of BG values of a typical single 
artificial patient,  as a characteristic of the group to which the patient belongs.  In brief, the blood 
glucose data of each group member is transformed logarithmically.  The mean and the SD of the 
logarithmically-transformed blood glucose data are determined for each patient in the group.  For the 
collection of the glucose means of the logarithmically-transformed data of each patient, a group mean is 
computed, with its own SD, “in log space.”  Using the logarithmically-transformed glucose values, for the 
collection of SDs for each patient a group mean is computed, with its own SD, again “in log space.”  If 
groups of patients are to be compared using parametric or nonparametric tests, the comparisons should 
be performed “in log space”  (Figure 1). 
 Reverse-transformation is accomplished using the same base of the logarithm that was used 
during the initial logarithmic transformation of the BG values.  The group mean of the patient means of 
logarithmically-transformed BG is reverse-transformed to give the GGM.   After reverse-transformation, 
the interval bounds of the 1st and 2nd SD will be asymmetric about the GGM.   Reverse-transformation 
“from log space” of (mean   – SD,  mean  + SD) and (mean  – 2 SD, mean +2 SD) gives interval bounds for 
GGM having the same predictive value as the 1st and 2nd SD determined “in log space” prior to reverse-
transformation,  i.e. that 67% of values for the population would fall within the 1st SD and 95% within 
the 2nd SD.   Alternatively, if the mean and its SD are reverse-transformed  “from log space” separately, 
the reverse-transformed SD becomes a multiplicative standard deviation (MSD) for the GGM 11.  The 
same values for  interval bounds associated with the 1st and 2nd SD then are given after reverse-
transformation by (GGM ÷ MSD, GGM × MSD) and (GGM ÷  MSD2, GGM × MSD2).    The GGM is a group 
metric for central tendency of the patient  BG.   
 The group mean of the patient SDs of logarithmically-transformed BG is reverse-transformed to 
give the MSSD.  The interval bounds associated with the  1st and 2nd SD prior to reverse-transformation 
”from log space”  then are given by reverse-transformation of each of the interval bounds (mean   – SD),  
(mean  + SD) and (mean  – 2 SD), (mean +2 SD).  Alternatively, if the mean and its SD are reverse-
transformed  “from log space” separately , the same values for interval bounds associated with the 1st 
and 2nd SD then are given after reverse-transformation by (MSSD ÷ MSD, MSSD × MSD) and (MSSD ÷  
MSD2, MSSD × MSD2).    The MSSD is a group metric for variability of the patient  BG.   
 A true  SD is defined only in reference to a single mean.  The metric MSSD, derived after  
averaging the SD’s of transformed BG’s from multiple patients “in log space,”  is not paired with any 
specific single mean,  and therefore is not properly a SD.   Therefore, we suggest rather that the name 
should imply that that metric is a  “surrogate” for a SD.  This “SD surrogate” resembles a multiplicative 
SD .  The surrogate SD is unit-less.   This  “SD  surrogate” has magnitude  characteristic of a multiplicative 
SD.  When applied to a geometric mean BG that would be found  in a BG distribution typical for a 
member of the sampled population , the MSSD yields values for interval ranges comparable in 
magnitude to an actual SD.  If the MSSD is used in reference to GGM,  it is used as follows: 
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Method applied to demonstration data set 
Previously published data will be used to demonstrate the method of analysis 9.  The data set is found at  
http://www.journalofdst.org/Journal/pdf/July2008/VOL-2-4-ORG4-CHASE-DATA-SUPPLEMENT-DS1.XLS 
For the present, a subset of BG data from time zero to 72 hr inclusive was examined for each patient in 
the cohort reported by Chase and colleagues, a time interval chosen because each patient continued to 
have data beyond 72 hr but also judged brief enough to capture differences in initial glycemic variability 
between patients 9.  Some patients experienced brief gaps in data or compliance noted, but none were 
removed from treatment under the SPRINT algorithm for longer than 2 hr during the interval of data 
collection.     
 The BG data set of each patient was logarithmically-transformed.   The SDs of the 
logarithmically-transformed BG data sets were rank-ordered, and the 20 patient members of the cohort 
were divided into two groups,  having SD’s of the transformed BG data set of each patient that were 
either below or above a value between the two median SD values , i.e. into “lower variability” and 
“higher variability” groups, each having 10 members .     
 The term “overall” when applied to mean or SD of a BG distribution will refer to the application 
of the metric to the set of all eligible BG data of the cohort (or a subgroup), using the BG as the unit of 
observation.  For the entire cohort, and for the lower and higher variability patient subgroups 
separately, metrics were described in each of 4 ways (Table 1):  (1) metrics from untransformed overall 
BG data;  (2) metrics from untransformed BGs  of each patient ;  (3) reverse-transformed metrics from 
logarithmically-transformed overall BG data;  and (4) reverse-transformed metrics  from logarithmically-
transformed BG data of each patient.  As final steps, reverse-transformed measures of central tendency, 
arithmetic SD’s, and interval bounds were converted to SI units, and results were rounded so as to have 
no decimal places.  After use for other calculations, MSD’s and MSSD in a final step were rounded to 2 
decimal places for presentation as results.  
 The numbers of untransformed BG values were counted and proportions were determined that 
lay within  ± 1 SD or ± 2 SD or outside of 2 SD of the mean of the untransformed and logarithmically 
transformed overall BG data, and that lay within 1 MSSD or 2 MSSD of GGM or outside of 2 MSSD of 
GGM, for the entire cohort and separately for the lower and higher variability subgroups. 
 Using the unpaired two-tailed T-test with samples having unequal variance, first the overall 
means of the logarithmically-transformed overall BG data between the lower-variability and the higher-
variability patient subgroups were compared, and then the patient means and SD’s of the two groups 
were compared.   
 
 GGM,          GGM  ÷  MSSD,    GGM  ×  MSSD  
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RESULTS 
The frequency distribution of BG values is shown for the overall BG values of each of the two groups of 
10 patient in Figure 2.  The results of 4 methods of analysis of each group are shown in Table 1 for the 
entire cohort and for the lower and higher variability patient subgroups.  In methods (3) and (4) the 
initial logarithmic transformation converts the data into the form used for development of means and 
SD’s and for  statistical testing , after which, in each method, the means and interval bounds are reverse-
transformed monotonically to yield the results shown.    
 When the patient subgroups with lower and higher variability were compared with respect to 
their logarithmically-transformed overall BG datasets, consisting of 527 measurements from the lower 
variability subgroup and 505 measurements from the higher variability subgroup of patients,  the mean 
overall value of the logarithmically transformed BG of the two subgroups differed ( p = 0.0027).   In 
method (3), the overall means ± SD of the logarithmically transformed BGs for the lower and higher 
variability subgroups were 0.760562663 ± 0.072367226 vs.  0.779476971 ± 0.122302184 respectively, 
which are  reverse-transformed  to means and MSD’s of 104 (÷ / × 1.18) vs. 108 (÷ / × 1.33) mg/dL.  
When the 10 means and 10 SD’s  from the logarithmically-transformed BG data sets of all patients 
within each of the two subgroups were compared,  the means of the means did not differ ( p = 0.16), but 
the means of the SD’s differed, p < 0.00004. After reverse-transformation, the GGM’s with MSD were 
104 (÷ / × 1.07)  vs. 109 (÷ / × 1.07) mg/dL for the patient groups having the lower and higher variability 
respectively.   Expressed in unit less numbers,  the corresponding MSSD’s with MSD’s were 1.17 (÷ / × 
1.03)  vs. 1.31 (÷ / × 1.05).   Under methods (1). (3) and (4), the actual counts and percentage of BG 
results from the sampled groups falling within the range of interval bounds are stated for comparison 
with the statistical prediction for the population.   For each of the two groups of 10 patients, the percent 
of overall BG values for the entire group falling within interval bounds is shown graphically for methods 
(1), (2), (3), and (4) in Figure 3. 
DISCUSSION 
The performance of several metrics for evaluation of glycemic variability in the hospital has recently 
been reviewed  6. Here we are focusing on proposed improvements to the use of SD as a variability 
metric.  First, it is important to ensure stability of a measure of central tendency during the time of 
observation, if SD is intended to reflect variability.  Second, in this discussion, we address a solution to 
the problem of the distribution of BG, which characteristically requires transformation for appropriate 
use of SD for descriptive purposes or performance of parametric statistical comparisons.  Third, we 
focus on the importance of using the patient as the unit of observation for BG metrics, rather than the 
BG. 
 The authors do not advocate either of the approaches (1) or (2) shown in Table 1, but display 
the results for comparison, recognizing that historically important publications on the subject of 
glycemic variability have used untransformed raw BG data.   Although glycemic variability was not the 
principal focus of the article, the first method, using the BG as the unit of observation, was employed in 
the Leuven, Belgium 2001 trial of intensive glycemic control in the surgical ICU 12.  The second method of 
analysis was used by two pivotal observational reports about the interaction between glycemic 
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variability and outcomes 1,2.   By using the raw data of the patient as the unit of observation, it was 
possible to correlate SD with individual outcomes. 
 Reverse-transformation will monotonically preserve the order of  BG values and the values of 
the interval bounds.  As is true in general for multiplicative SD for positively skewed data, after 
logarithmic transformation the interval bounds are asymmetric about the measure of central tendency, 
with a wider range above than below.   For an excellent visual depiction, the reader is directed to the 
two-panel  Figure 3 in the paper by Limpert et al., which shows the distribution of idealized hypothetical 
data, drawn as a continuous curve11.   Using discrete patient data, a graphical comparative display of the 
untransformed and transformed BG distribution of sample cases has been published by Palerm and 
colleagues 10.  The effect of transformation is to compress the long right-hand end of the curve, so that 
the peak of the redrawn curve after logarithmic transformation is centered on the mean of the 
transformed data.   In the present study, as is true in general for  geometric means of positively skewed 
data, in comparison to arithmetic means, the reverse-transformed metrics  for central tendency shown 
in methods (3) and (4) are lower than the arithmetic means  shown in methods (1) and (2).  The positive 
skew of untransformed BG data is more apparent in the group having higher variability (Figure 2).     
 Reverse-transformed metrics may improve the predictive credibility of the  interval bounds for 
overall group BG data.  In the present study, under methods (3) and (4), the mean and SD of 
logarithmically-transformed BG data were used to establish interval bounds.   Compared to use of 
metrics based on untransformed data under methods (1) and (2),  the improvement of symmetry of BG 
measurements about the mean, and the actual percentage distribution of BG measurements between 
the values demarcated by the mean, 1st and 2nd interval bounds, suggest that the distribution of the 
logarithmically-transformed BG’s has approached a normal distribution (Figure 3).    
 A limitation of the method of use of logarithmic transformation, reverse transformation, and 
multiplicative SD is the effect of rounding .  The final results here are expressed to 2 decimal places for 
the multiplicative SD, and none for BG in mg/dL.  A limitation of the present study is that it has not been 
convincingly demonstrated from a large sample of patients whether or not the collection of means or 
SD’s of transformed BG’s of each patient would yield a normal distribution of these means or SD’s.  In 
case future evaluation shows deviation from a normal distribution, non-parametric testing could be 
used to compare distributions of these means or SD’s.   
 From the complete data set of the cohort of ICU patients published by Chase and colleagues, the 
reported overall glycemic average of reverse-transformed BG data was 105 mg/dL, with a first 
multiplicative SD of 1.2x, yielding a predicted 66% one-SD range of 86-126 mg/dL and a 95% two-SD 
range of 72-151 mg/dL.  Using method (3) in Table 1, we performed a similar analysis of overall results 
for the same cohort, using logarithmically-transformed BGs, but restricting the data to the first 72 hr of 
treatment .   The overall mean BG after reverse-transformation was 106.1 mg/dL with  a one-SD range of 
84.2-133.6 mg/dL and a 2-SD range of 66.8-168.4 mg/dL.     
 Taken together, in method (4) the GGM and MSSD describe an artificial patient.  who may be 
seen as a typical member of a group. The choice of the term “artificial” results from the use of a 
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surrogate value for the  MSSD and the creation of a GGM, which is actually a reverse-transformed mean 
of means.   The principal advantage of method (4) is that the status of individual patients according to 
variability becomes evaluable.  Going forward, in the field of glycemic control, we need to become 
sensitized to recognizing ranges of multiplicative SD values that are low or high, without mentally 
applying them  to a mean BG.  However, the reverse-transformation permits expression of the GGM and 
interval bounds  in familiar units of measure.  The MSSD and GGM are not mathematically linked in the 
same obligatory manner as a true SD is linked to the distribution of BGs associated with its mean.  It 
cannot be predicted that 67% of measurements from the randomly sampled population will fall within 1 
MSSD of the GGM or 95% within 2 MSSD or the GGM.  If all patients in the population had the statistics 
of the BG distribution described for the artificial patient (or if there was only one patient), then 67% of 
BG values overall for the population would fall within the first interval bounds, and 95% within the 
second interval bounds. 
 Use of parametric testing dependent upon mean and SD for group comparisons requires that 
each group have an approximately normal distribution.   Differences between groups in the protocol-
controlled population reported here were not demonstrable prior to logarithmic transformation of data.  
After logarithmic transformation of BGs, using method (3) and method (4), it was possible to identify 
subgroups with different variability, shown in Table 1 as the middle and right-hand columns.  A 
difference of the overall mean BG was demonstrable statistically only when using method (3) to 
compare the 527 vs. 505 overall BG values of the two groups of 10 patients each.    
 The demonstration data patient group was tightly controlled under the SPRINT protocol, having 
a single target range 13.  One might envision a different situation in which algorithm designs or 
institutional protocols were capable of aiming at more than one target range, having for example one 
default target range for general critical care and a second target range for diabetic ketoacidosis 14,15.    
The overall BG distribution after reaching target range control then might exhibit a bimodal pattern, 
with overall mean intermediate between the two targets.  Ideally the mean BG values for each patient 
would cluster into the differing target ranges, appropriate to the conditions of the patients.  The overall 
SD of BG’s considered collectively for the group might overestimate the variability experienced by 
individual patients.  The SD for the BG of each patient then need not be a high value, but might be 
proportionate to the mean BG achieved, probably with similar coefficient of variability (CV) between 
patients.  These two theoretical examples -- (a) tight control of central tendency despite differences of 
individual variability, and (b) differences of central tendency despite  tight control of individual 
variability -- are used to emphasize the potential importance of patient-level determination of group 
metrics for central tendency and variability.    
 It is proposed that the GGM may be used to study the relationship of overall glycemia to 
outcomes and also the effectiveness of algorithms in achieving desired targets for groups or subgroups 
of patients.  The GGM describes the central tendency characteristic of patient members of a group,  and, 
although the GGM entails logarithmic transformation,  by reverse-transformation GGM expresses the 
central tendency metric  in units familiar to the reader.   
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 There is a need to examine the impact of variability upon the outcomes of individual patients.  In 
order to do so, a metric is required by which the variability of a patient can be compared to the typical 
variability that is characteristic of a patient member of his or her group.    In particular, as variability is 
associated with individual patient outcomes, then there is a need to present patient-specific variability 
metrics, but also, as presented here, to group those metrics in a concise and useful way in presenting 
and analyzing larger studies.  We propose that the MSSD is a candidate metric  expressed in familiar 
units of measure that may be used to described the typical variability of an individual group or subgroup 
member,  for study of relationship of patient variability to outcomes. 
   The proposed metrics GGM and MSSD have been developed and validated in a very small set of 
patients.   We should seek to evaluate variability as a predictor of outcomes, independent of 
hypoglycemia or severe hyperglycemia.  Assuming prevention of hypoglycemia can be achieved, it may 
be argued that we do not know the relative burden of medical strategies that might minimize variability, 
as compared to any burden resulting from glycemic variability itself.  Improvements in insulin algorithms 
and the development of non-insulin-based strategies may permit future studies to be conducted that 
may randomize patients to greater or lesser glycemic variability without significant differences in 
hypoglycemia.  Evaluation eventually will be required to examine the ability of  GGM and MSSD, 
compared to other metrics for variability and central tendency, to predict nonglycemic outcomes .     
CONCLUSIONS 
The GGM and MSSD are presented as group metrics, requiring logarithmic transformation of the BG 
data set of each patient.    Development of statistics before a final reverse-transformation permits 
identification of predictive interval bounds and application of statistical testing for group comparisons. 
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Table 1.  Group Metrics for Central Tendency and Variability of Blood Glucose 
  
 
Entire cohort 
Lower 
variability 
subgroup a 
Higher  
variability 
subgroup a 
Number of patients  20 10 10 
Number of BG results  1032 527 505 
(1a)   Metrics from untransformed overall BG data     
    (n = number of BG results)    
 Overall mean in mg/dL  109 105  113  
  (±  overall SD in mg/dL) (± 28) (±  17)  (±  35) 
 Interval bounds in mg/dL,  ±  1 SD (82 – 137) (88 – 123) (78 – 148) 
 Interval bounds in mg/dL,  ±  2 SD (54 – 164) (71 – 140) (43 – 183) 
(1b)  Distribution of BG’s    
 Number (%) of BG within mean ±  1 SD’s b 814  (78.9%) 384 (72.9%) 394 (78.0%) 
 Number (%) of BG within mean  ±  2 SD’s b 986  (95.5%) 499 (94.7%) 486 (96.2%) 
(2)   Metrics from untransformed BGs of each 
patient  in mg/dL      
   
    (n = number of patients)    
 Mean of BG means of each patient 109 106 113 
 Mean of SD’s of each patient 24 16 32 
(3a)   Reverse-transformed metrics from 
logarithmically-transformed overall BG data 
   
    (n = number of BG results)    
 Overall mean BG in mg/dL   106 104 
c 108 c 
 (÷ / ×  overall MSD) (÷/× 1.26) (÷/× 1.18) (÷ /× 1.33) 
Interval bounds in mg/dL within 1st  MSD  (84 – 134) (88 – 123) (82 – 144) 
Interval bounds in mg/dL within 2nd MSD  (67 – 168) (74 – 145) (62 – 191) 
(3b) Distribution of BG’s    
Number (%) of BG within 1st  MSD  788  (76.4%) 384  (72.9%) 370  (73.3%) 
Number (%) of BG within 2nd MSD  975  (94.5%) 499  (94.7%) 480  (95.0%) 
(4a) Reverse-transformed metrics  from 
logarithmically-transformed BG data                                
of each patient      
   
    (n = number of patients)    
 GGM  in mg/dL 106 104 109 
  ( ÷ / ∗  1 MSD of GGM) (÷ / × 1.07)  (÷ / × 1.07)  (÷ / × 1.07) 
 MSSD  1.24 1.17 
d 
    1.31 
d
 
  ( ÷ / ∗ 1 MSD of MSSD) (÷ / × 1.07)  (÷ / × 1.03)  (÷ / × 1.05) 
 GGM  in mg/dL, ÷ / ∗ MSSD once (86 – 132) (89 –122) (83 – 142) 
 GGM  in mg/dL, ÷ / ∗  MSSD twice (70 – 163) (76 – 142) (64 – 186) 
(4b) Distribution of BG’s    
 Number (%) of BG within  1 MSSD of GGM* 754 (73.1%) 360 (68.3%) 360 (71.3%) 
 Number (%) of BG within  2 MSSD of GGM* 959 (92.9%) 491 (93.2%) 478 (94.7%) 
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Footnotes to Table 1. 
BG = blood glucose 
SD = standard deviation 
MSD = multiplicative standard deviation 
GGM = group geometric mean 
MSSD = multiplicative surrogate standard deviation 
a  The SDs of the logarithmically-transformed BG data sets were rank-ordered, and the patient members 
of the cohort were divided into lower and upper halves (see text)  
b  The actual counts of BG results from the sampled groups are given 
c   p =  ( p = 0.0027).    
d  p  < 0.00004 
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Legend for Figure 1. 
A process is depicted  for calculation of geometric group mean (GGM) and multiplicative surrogate 
standard deviation (MSSD), intended to permit characterization and comparison of groups of 
hospitalized patients according to glycemic variability of patient members of each group.  In case the 
collection of means or SD’s of transformed BG’s of each patient does not  yield a normal distribution of 
these means or SD’s, instead of using the standard deviation (SD), it would be appropriate to consider 
interquartile ranges and to use non-parametric testing for comparisons.   
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Legend Figure 2.  The overall frequency distribution for each of two patient groups (n=10 in each group) 
described in the text is shown as the number of blood glucose (BG) measurements falling within bins of 
BG concentration incrementally increasing from left to right by 10 mg/dL between markers.  
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Figure 3.  Interval bounds are established under each of four methods with reference to the following 
metrics:  the mean and SD using untransformed overall BG data (method 1); the mean of BG means and 
the mean of SD’s of each patient, using untransformed BGs of each patient (method 2); the overall 
geometric mean and multiplicative SD (MSD) using reverse-transformed metrics from logarithmically-
transformed overall BG data (method 3); and the reverse-transformed mean of means (group geometric 
mean, GGM) and mean of SD’s (multiplicative surrogate standard deviation, MSSD) of logarithmically-
transformed BG data of each patient (method 4).  Interval bounds (< -2; -2 to -1; -1 to mean; mean to +1; 
+1 to +2; and > +2) refer to values obtained by use of a mean and an arithmetic SD (Panel A), or a 
geometric mean and multiplicative SD (Panel B), to define ranges bounded by BG values.  The interval 
bounds in methods 1 and 2 equal mean ± 1 or ± 2 SD’s.  The interval bounds in method 3 equal 
geometric mean (÷ / x MSD) or geometric mean (÷ / x MSD2).  The interval bounds in method 4 equal 
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GGM (÷ / x MSSD) or (÷ / x MSSD2).  To determine the percent of BG measurements falling within 
interval bounds, each of the four methods of metrics for central tendency and variability is applied to 
the overall BG data of two patient groups described in the text (n = 10 patients in each group, having 
lower and higher variability), to determine percent of BG’s (n=527 and 505 BG measurements in the 
lower and higher variability groups respectively) within the interval bounds defined under each method. 
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